Anti-obesity Drugs: Guidance on Appropriate Prescribing and Management |
Common terms and phrases
12 weeks Anti-obesity drug therapy anti-obesity drug treatment appropriate behaviour modification benefits blood pressure body mass index case-control or cohort cholesterol clinical assessment clinician Consultant Physician continue Contraindications demonstrating overall consistency diet dietary diethylpropion discontinued disease documentation dose Duration of treatment dyslipidaemia energy intake established comorbidities exercise and behaviour Extrapolated evidence Gastroenterologist gastrointestinal system guidance Hospital Human Nutrition hypercholesterolaemia hypertension individuals initial body weight Institute for Clinical kg/m² lifestyle change longer-term low risk management of overweight management pathway MD FRCP measures Medical Council metabolic Monitoring Newcastle upon Tyne obese patients obesity drug orlistat and sibutramine overweight and obesity overweight or obese pancreatic lipase inhibitors phentermine prescribed prescription product licence Professor of Clinical programme regular physical reviews of RCTs risk factors serotonin sleep apnoea stadiometer syndrome systematic reviews target population type 2 diabetes University of Southampton waist circumference weight loss goals weight reduction weight regain